

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Health Technology Evaluation

Equality impact assessment – Scoping

Tisotumab vedotin for treating recurrent or metastatic cervical cancer that has progressed on or after systemic treatment [ID3753]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1.	Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?
It was highlighted during scope consultation that cervical cancer rates are higher in deprived areas and that screening rates are lower in women in deprived populations.	
It was also highlighted that HPV vaccine uptake is lower among both more deprived and non-white populations.	
2.	What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?
NICE considers appraisal technologies within their marketing authorisation for the whole population, and for relevant subgroups as defined in section 4.9 of the NICE health technology evaluations manual. As part of the technology appraisal, the committee will also consider the impact of recommendations on people with protected characteristics and the potential impact on health inequalities as outlined in the NICE Principles .	
3.	Has any change to the draft scope been agreed to highlight potential equality issues?
No	

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?
--

None.

Approved by Associate Director (name): Janet Robertson

Date: 30 June 2025